Advertisement

Topics

Latest "Euronext N.V" News Stories

08:30 EDT 21st October 2017 | BioPortfolio

Here are the most relevant search results for "Euronext N.V" found in our extensive news archives from over 250 global news sources.

More Information about Euronext N.V on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Euronext N.V for you to read. Along with our medical data and news we also list Euronext N.V Clinical Trials, which are updated daily. BioPortfolio also has a large database of Euronext N.V Companies for you to search.

Showing "Euronext" News Articles 1–25 of 264

Friday 20th October 2017

DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age

  Press Release   Montrouge, France, October 20, 2017 DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced topline results from the PEPITES (Peanut EPIT Efficacy and Safety) Phase III trial evaluating...


General Electric Company: GE files Form 8-K

FAIRFIELD, CT -- (Marketwired) -- 10/20/17 -- General Electric Company (LSE: GEC) (EURONEXT PARIS: GNE) Company: General Electric Company ISIN: US3696041033 Symbol: London: GEC | Paris: GNE Headli...

Nicox Enters Research Collaboration with Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation

Press Release Nicox Enters Research Collaboration with  Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation   October 20, 2017 - release at 7:30 am CET Sophia Antipolis, France and Belfast, Northern Irelan


ThromboGenics Business Update - Q3 2017

Press release                                                          20 October, 2017Regulated Information Diabetic Eye Disease programs progressing €53.7 million cash received from Alcon/Novartis in conjunction with regaining the non-US rights to JETREA Company's end Q3 2017 cash position €113.4 million

Thursday 19th October 2017

Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight

Paris, 19 October 2017, 5.45pm Preclinical data showing protective effect of masitinib on the peripheral nervous system in amyotrophic lateral sclerosis (ALS) published in the Journal of Clinical Investigation Insight AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs),...

Transgene: Third Quarter Marked by Progress in Clinical Development and Research

2 new clinical trials started during the third quarter Launch of the Invir.IOTM platform (next generation of multifunctional oncolytic viruses) and collaboration with Randox €40.0 Million in cash and cash equivalents as of September 30, 2017 and cash burn in line with expectations Regulatory ...

Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan

Vivian Wang and Takashi Hayashi will strengthen Median’s growth in Asia. With these appointments, and the recently announced opening of its subsidiary in Hong Kong, Median intends to significantly invest in and grow its business in the Asian market. Regulatory News: Median Technologies (Paris:ALMDT...

Pixium Vision Receives Approval for First-in-Human Clinical Trial of PRIMA, Its Miniaturized Sub-Retinal Implant

French regulatory Authority, ANSM, approves PRIMA’s feasibility study for advanced dry-AMD Pixium Vision (FR0011950641 - PIX)(Paris:PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, today announces that its next-generation miniaturized wireless sub-retinal implant,...

Wednesday 18th October 2017

Lysogene Announces Company Presentations at Upcoming Scientific Conferences

Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in and presenting at several scientific events in the upcoming weeks. A detailed list of the October and November events is a...

Ipsen and Exelixis’ Cabozantinib Meets Primary Endpoint in Phase 3 Hepatocellular Carcinoma Trial

PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and its partner Exelixis (NASDAQ: EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with advanced hepatocellular ...

Dassault Systèmes’ Living Heart Project Reaches Next Milestones in Mission to Improve Patient Care

Simulated digital 3D heart model now on the cloud offers new perspectives for medical research Project grows to 95 worldwide members, extends to simulating drug interactions with heart Supports FDA focus on simulation and modeling through the 21st

Tuesday 17th October 2017

ASIT biotech Announces the Grant of a European Patent on the Active Ingredients Used in the ASIT+™ Allergy Immunotherapy Product Candidates

BRUSSELS–(BUSINESS WIRE)–Regulatory News: ASIT biotech (Euronext: ASIT – BE0974289218) (Paris:ASIT) (BSE:ASIT), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announces the positive decision of the European … Continue reading → C...

ASIT biotech Announces the Grant of a European Patent on the Active Ingredients Used in the ASIT+ Allergy Immunotherapy Product Candidates

Regulatory News: ASIT biotech (Euronext: ASIT BE0974289218) (Paris:ASIT) (BSE:ASIT), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercializ...

Median Technologies to Attend The Liver Meeting® of The American Association for the Study of Liver Diseases to Be Held October 20-24, 2017 in Washington, DC, USA

Median Technologies will showcase its iBiopsy® platform for liver diseases at booth #241 The Imaging Phenomics Company® is now a registered trademark of Median Technologies Regulatory News: Median Technologies (Paris:ALMDT), the Imaging Phenomics Company®, announced today that it will part...

Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B

Data Featured in a Poster Presentation at AASLD Liver Meeting 2017 Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, will be presenting a poster on TG1050 first promising clinical results at the American Association for the Study of Liver Diseases (AASLD) Mee...

Mauna Kea Technologies Appoints Olivier Regnard as Deputy CEO And Chief Financial Officer

Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer, effective immediately. Mr. Regnard brings nearly 20 years of fina...

Ablynx: ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 17 October 2017 - Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY], a late-stage clinical biopharmaceutical company utilising its propriet...

GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANEs") DUE 2022

 GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANEs") DUE 2022 Lille (France), Cambridge (Massachusetts, United States), October 17th, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabo...

Monday 16th October 2017

Poxel Announces Third Quarter 2017 Financial Update

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announced today its cash position for the third quarter of 2017. As of September 30, 2017, cash and cash equivalents were €30.0 million (U.S.$35.4 million). As expected,...

Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and its partner Exelixis (NASDAQ: EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with advance...

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris: SIGHT), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced multiple data presentations at the Congress of the European Society ...

Thursday 12th October 2017

Medicrea Reports Third Quarter 2017 Sales

The Medicrea Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, publishes its sales for the 3rd quarter ended September 30, 2017.     ...

EOS imaging Reports 28% Sales Growth for the Third Quarter 2017

Appoints Eric Maulavé as Chief Operating Officer EOS to present new solutions to enhance communication between radiologist, patient and referring physician at Journées Francophones de Radiologie meeting EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - SME), the pioneer of orthopaedic medical imaging, 2D/3D, today anno...

Transgene: Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors

Transgene Is Currently Developing TG4010 in Advanced Lung Cancer (NSCLC) in Combination Regimens with Immune Checkpoint Inhibitors (ICIs) Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops viral-based immunotherapies, recently published two papers supporting the efficacy and mechanism of action of its therapeut...

News Release: New achievement towards the combination of Essilor and Luxottica - Hive-down of Essilor's activities

New achievement towards the combination of Essilor and LuxotticaHive-down of Essilor's activities PDF Version of the news release Charenton-le-Pont, France (October 12, 2017 - 8:30 a.m.) - On October 3, 2017, the Board of Directors of Essilor International (Compagnie Générale d'Optique) («Essilor») confirmed that the hive-down of Essilor's activities...


Quick Search
Advertisement
 

News Quicklinks